SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

In its new guidelines, the American Heart Association says not all ultraprocessed foods are so bad — such as whole grain breads, low-sugar yogurts, tomato sauces, and nut or bean-based spreads. The ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

In its second-quarter financial filing, Iovance said it was planning to shed 19% of its workforce of more than 630 in order ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The FTSE 100 began the day on a cautious note, opening slightly higher but failing to erase the previous session’s losses.

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...